TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to ARV Treatment and Its Effects on Medium Run Socio-Economic Outcomes: Evidence From Western Kenya
Brief Summary: The purpose of proposed research is to implement a randomized study that will allow us to understand and address a number of key barriers to patient adherence as well as study the effects of better adherence on health and socio-economic outcomes.


Options:
A: Arm Label: Weekly SMS, brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Weekly SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Intervention Type: BEHAVIORAL; Name: Short Message Services to Support ARV therapy adherence; Assigned to Arm(s): Control Group, Daily SMS, Brief message, Daily SMS, Long Message, Weekly SMS, Long Message, Weekly SMS, brief message
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1
D: Arm Label: 1 Standard Care (SC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Standard Care + Educational (SCE); Type: OTHER; Interventions: Behavioral: educational instruction in clinic | Arm Label: 3 Standard Care + Educational + Phone Calls (SCEP); Type: OTHER; Interventions: Behavioral: educational instruction and phone follow-up | Intervention Type: BEHAVIORAL; Name: educational instruction and phone follow-up; Assigned to Arm(s): 3 Standard Care + Educational + Phone Calls (SCEP) | Intervention Type: BEHAVIORAL; Name: educational instruction in clinic; Assigned to Arm(s): 2 Standard Care + Educational (SCE)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to ARV Treatment and Its Effects on Medium Run Socio-Economic Outcomes: Evidence From Western Kenya
Brief Summary: The purpose of proposed research is to implement a randomized study that will allow us to understand and address a number of key barriers to patient adherence as well as study the effects of better adherence on health and socio-economic outcomes.


Options:
A: Arm Label: Weekly SMS, brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Weekly SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Intervention Type: BEHAVIORAL; Name: Short Message Services to Support ARV therapy adherence; Assigned to Arm(s): Control Group, Daily SMS, Brief message, Daily SMS, Long Message, Weekly SMS, Long Message, Weekly SMS, brief message
B: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
D: Arm Label: Arm 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Medication Management with Home BP Telemonitoring | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Combined intervention with Home BP Telemonitoring | Intervention Type: BEHAVIORAL; Name: Nurse Behavioral intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Nurse Medication Management with Home BP Telemonitoring; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: Nurse Combined intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to ARV Treatment and Its Effects on Medium Run Socio-Economic Outcomes: Evidence From Western Kenya
Brief Summary: The purpose of proposed research is to implement a randomized study that will allow us to understand and address a number of key barriers to patient adherence as well as study the effects of better adherence on health and socio-economic outcomes.


Options:
A: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
C: Arm Label: Weekly SMS, brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Weekly SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Intervention Type: BEHAVIORAL; Name: Short Message Services to Support ARV therapy adherence; Assigned to Arm(s): Control Group, Daily SMS, Brief message, Daily SMS, Long Message, Weekly SMS, Long Message, Weekly SMS, brief message
D: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Brief Summary: The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative colitis (UC).


Options:
A: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo
B: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
C: Arm Label: Mesalazine once/day; Type: EXPERIMENTAL; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Arm Label: Mesalazine twice/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Intervention Type: DRUG; Name: Mesalazine slow-release granules; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day | Intervention Type: DRUG; Name: Mesalazine liquid enema; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day
D: Arm Label: TP05 (Mesalazine) 1600mg; Type: EXPERIMENTAL; Interventions: Drug: TP05 | Arm Label: Asacol 400 mg (Tillotts Pharma); Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg | Intervention Type: DRUG; Name: TP05; Assigned to Arm(s): TP05 (Mesalazine) 1600mg | Intervention Type: DRUG; Name: Asacol 400 mg; Assigned to Arm(s): Asacol 400 mg (Tillotts Pharma)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Brief Summary: The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative colitis (UC).


Options:
A: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
B: Arm Label: Dersalazine; Type: EXPERIMENTAL; Interventions: Drug: Dersalazine sodium | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dersalazine sodium; Assigned to Arm(s): Dersalazine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mesalazine once/day; Type: EXPERIMENTAL; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Arm Label: Mesalazine twice/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Intervention Type: DRUG; Name: Mesalazine slow-release granules; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day | Intervention Type: DRUG; Name: Mesalazine liquid enema; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day
D: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Brief Summary: The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative colitis (UC).


Options:
A: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
B: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Open Label; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 1: Open Label
C: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
D: Arm Label: Double Blind; Type: PLACEBO_COMPARATOR; Interventions: Biological: adalimumab, Biological: placebo | Arm Label: Open Label; Type: OTHER; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Open Label

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Expression of Longevity Genes in Response to Extended Fasting
Brief Summary: The purpose of this study is to evaluate the effect of fasting on physical changes associated with cardiovascular disease.


Options:
A: Arm Label: Fasting Day First; Type: OTHER; Interventions: Behavioral: Fasting First | Arm Label: Fed Day First; Type: OTHER; Interventions: Behavioral: Fed First | Intervention Type: BEHAVIORAL; Name: Fasting First; Assigned to Arm(s): Fasting Day First | Intervention Type: BEHAVIORAL; Name: Fed First; Assigned to Arm(s): Fed Day First
B: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo
C: Arm Label: Breakfast Rest; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Breakfast | Arm Label: Breakfast Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Dietary Supplement: Breakfast | Arm Label: Fasted Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Breakfast Exercise, Fasted Exercise | Intervention Type: DIETARY_SUPPLEMENT; Name: Breakfast; Assigned to Arm(s): Breakfast Exercise, Breakfast Rest
D: Arm Label: TRF; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restricted Feeding | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Time Restricted Feeding; Assigned to Arm(s): TRF | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)
Brief Summary: This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy. The study will provide information for doctors on how to manage the transfer from methotrexate to the biologic agent ustekinumab. The study is designed to compare two methods of transferring patients from methotrexate to ustekinumab. The two methods being compared are discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.


Options:
A: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate
C: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)
Brief Summary: This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy. The study will provide information for doctors on how to manage the transfer from methotrexate to the biologic agent ustekinumab. The study is designed to compare two methods of transferring patients from methotrexate to ustekinumab. The two methods being compared are discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate
C: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg

Answer: B